©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 8, 2015; 7(13): 1730-1734
Published online Jul 8, 2015. doi: 10.4254/wjh.v7.i13.1730
Published online Jul 8, 2015. doi: 10.4254/wjh.v7.i13.1730
Changing common sense: Anti-platelet/coagulation therapy against cirrhosis
Yoshihiro Ikura, Department of Pathology, Takatsuki General Hospital, Takatsuki 569-1192, Japan
Tatsuya Osuga, Department of Gastroenterology, Takatsuki General Hospital, Takatsuki 569-1192, Japan
Author contributions: Ikura Y designed the concept and wrote the manuscript; Osuga T designed the concept, prepared the figures and checked the manuscript.
Conflict-of-interest statement: None.
Correspondence to: Yoshihiro Ikura, MD, Department of Pathology, Takatsuki General Hospital, 1-3-13, Kosobecho, Takatsuki 569-1192, Japan. ikura@ajk.takatsuki-hp.or.jp
Telephone: +81-72-6813801 Fax: +81-72-6823834
Received: January 25, 2015
Peer-review started: January 27, 2015
First decision: March 20, 2015
Revised: March 29, 2015
Accepted: April 28, 2015
Article in press: April 30, 2015
Published online: July 8, 2015
Processing time: 166 Days and 2.2 Hours
Peer-review started: January 27, 2015
First decision: March 20, 2015
Revised: March 29, 2015
Accepted: April 28, 2015
Article in press: April 30, 2015
Published online: July 8, 2015
Processing time: 166 Days and 2.2 Hours
Core Tip
Core tip: Recognition concerning anti-platelet/coagulation therapy for cirrhotic patients has been changing from relative contraindication to recommendable. Administration of this type of drugs is expected to not only prevent cirrhosis-related thrombotic disorders but also slow down the progression of liver disease itself.